Combination may benefit certain patients with TP53-mutated myelodysplastic syndrome
NEW ORLEANS — A higher burden of mutant TP53 cells connoted poorer risk among adults with intermediate- or high-risk myelodysplastic syndrome, according to study results presented at ASH Annual Meeting and Exposition.
A fixed-dose combination of oral decitabine and cedazuridine (Inqovi; Astex Pharmaceuticals, Taiho Oncology) may be a reasonable treatment option for these patients, findings from a post hoc analysis of the randomized phase 3 ASCERTAIN trial showed.
Survival outcomes varied between patients with biallelic vs. monoallelic mutations.
Healio spoke with researcher Guillermo Garcia-Manero, MD, chief of the section of myelodysplastic syndrome and deputy chair of translational research in the department of leukemia at The University of Texas MD Anderson Cancer Center, about the study results and their potential implications.
Collapse
Savona MR, et al. Abstract 854. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.